Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

NCT03625323 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

187

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC
HNSCC

Interventions

DRUG: eftilagimod alpha
DRUG: pembrolizumab (KEYTRUDA®)

Sponsor

Immutep S.A.S.

Collaborators

[object Object]